Literature DB >> 31401050

Treatment duration of checkpoint inhibitors for NSCLC.

Jordi Remon1, Jessica Menis2, Sandrine Aspeslagh3, Benjamin Besse4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31401050     DOI： 10.1016/S2213-2600(19)30192-4

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  3 in total

1.  Cancer Treatment Adaptations in the COVID-19 Era.

Authors:  Federico Waisberg; Diego Enrico; Martín Angel; Matías Chacón
Journal:  JCO Oncol Pract       Date:  2020-04-23

2.  Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report.

Authors:  Yanhong Yao; Zhentao Liu; Qian Li; Baoshan Cao; Mopei Wang
Journal:  Thorac Cancer       Date:  2022-01-11       Impact factor: 3.500

Review 3.  Immunotherapy in malignant pleural mesothelioma: a review of literature data.

Authors:  Jessica Menis; Giulia Pasello; Jordi Remon
Journal:  Transl Lung Cancer Res       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.